Roth Capital Resumes Monopar Therapeutics (MNPR) at Buy
Tweet Send to a Friend
Roth Capital analyst Kumaraguru Raja, resumes coverage on Monopar Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
